Sentence examples for development of newer compounds from inspiring English sources

The resumption of tuberculosis led to an increased need to understand the molecular mechanisms of drug action and drug resistance, which should provide significant insight into the development of newer compounds.

During early-stage investigations, developing models in tandem with the development of new compounds, to predict safety concerns.

These results can be useful for the development of new compounds against SARS.

Thus, peptide aptamer 72 may be a useful tool for the development of new compounds specifically targeting poxvirus replication.

A main drawback in the development of new compounds is the lack of technologies to assess antagonist action in an in vitro situation as well as in living cells.

Therefore, the identification of the potential mechanisms of resistance to trastuzumab can be very helpful for the development of new compounds, which might overcome that resistance and/or have additive/synergistic antitumor effect when given in association with trastuzumab.

Therefore, clinical and preclinical AD research currently focuses strongly on the development of new compounds that address central histopathological features of AD including amyloid deposition, neurofibrillary tangle formation, and synapse loss.

Existing pharmacological treatments for mental disorders are not ideal, and there is much scope for the development of new compounds likely to be associated with improved effectiveness and acceptability in clinical practice.

This review highlights compounds in development for the treatment of tumours of the central nervous system which are structurally based on the indole, carbazole and indolocarbazole scaffolds, under the expectation that it will highlight new avenues for research for the development of new compounds to treat these devastating neoplasms.

The current paper reviews the advance in the past decade in this important domain of cancer chemoresistance and summarizes the development of new compounds and the re-evaluation of compounds originally designed for other targets as transport inhibitors of ATP-dependent drug efflux pumps.

Activists have railed against drug companies for dragging their heels in development of new compounds.